Welcome to our dedicated page for ABBOTT LABORATORIES SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ABBOTT LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ABBOTT LABORATORIES's regulatory disclosures and financial reporting.
ABBOTT LABORATORIES (ABT) officer John A. McCoy Jr., Vice President and Controller, reported share dispositions in early September 2026.
On September 2, 2026 he sold 27 common shares at $109.54 per share in a sale described as an open market or private transaction. On September 1, 2026, 52 common shares were delivered or withheld for payment of exercise price or tax liability at $110.36 per share. A separate entry shows 59 common shares held indirectly in the Abbott Laboratories Stock Retirement Trust, described as a Profit Sharing Trust, as of September 1, 2026. No Rule 10b5-1 trading plan is reported for these transactions.
ABBOTT LABORATORIES (ABT) executive vice president and chief financial officer Philip P. Boudreau reported a Form 4 showing that on September 1, 2026, 388 common shares were disposed of at $110.36 per share to satisfy exercise price or tax liability obligations. After this withholding, he holds 70,784 common shares directly, plus indirect holdings of 9,332 shares in the Abbott Laboratories Stock Retirement (Profit Sharing) Trust and 2,200 shares held by his spouse. No Rule 10b5-1 trading plan is affirmed.
ABBOTT LABORATORIES (ABT) received a Form 144 notice that John A. McCoy, Jr., identified as an officer, intends to sell 27 shares of common stock under Rule 144. The shares come from a restricted stock award that vested on September 1, 2026 and are to be sold on September 2, 2026 through UBS Financial Services, Inc. on the NYSE.
ABBOTT LABORATORIES (ABT) reported insider transactions by Chairman and CEO Robert B. Ford on 2026-08-25. He exercised employee stock options covering 398,832 common shares (151,869 at a $44.40 exercise price and 246,963 at $59.94), then sold a total of 398,832 common shares in open-market transactions at volume-weighted average prices in the $115–$116 range. In addition, 216,203 common shares are reported as held indirectly through the Ford Family Trust, where he serves as co-trustee.
ABBOTT LABORATORIES (ABT) received a Rule 144 notice from Robert B. Ford covering a proposed sale of its common stock. The notice indicates an intention to sell up to 398,832 shares of Abbott common stock through UBS Financial Services, Inc., with sales beginning on or after August 25, 2026. The shares are to be acquired via exercise of stock options for cash before being sold.
Abbott Laboratories (ABT) reported that it has entered into settlement agreements resolving the Missouri Gill case and necrotizing enterocolitis (NEC) claims involving approximately 2,000 additional infants relating to its specialty formulas for preterm infants. The aggregate settlement amount is approximately $670 million, described as a compromise of disputed claims and not an admission of liability.
The company had faced a $495 million jury verdict in the Gill case, which, with accrued interest, would have required payment of about $600 million absent further appeals or settlement. Abbott states it believes the agreements are in its long‑term interest and a constructive step toward substantially resolving the overall litigation. After these agreements, about 1,700 lawsuits remain pending involving claims on behalf of roughly 12,700 infants.
Abbott Laboratories executive Louis H. Morrone, Executive Vice President, reported transactions in common shares. On August 11, 2026, he sold 5,850 common shares in a non-derivative transaction at $109.83 per share, leaving 70,724 common shares held directly. On August 12, 2026, a discretionary transaction under Rule 16b-3(f) disposed of 12 indirectly held shares in a Profit Sharing Trust at $107.99 per share, leaving no shares reported under that indirect ownership.
Abbott Laboratories (ABT) reported a planned sale of common stock under a Form 144. A brokerage account at UBS Financial Services is listed in connection with 5,850 shares of common stock to be sold on the NYSE on or after August 11, 2026. The filing also references vested restricted stock awards dated February 27, 2026 in amounts of 1,960, 1,991, and 1,899 shares as the source of the securities to be sold.
Abbott Laboratories reported strong top-line growth for the quarter ended June 30, 2026. Net sales were $12.593 billion, up 13.0% year over year, with comparable sales growth of 4.8%. GAAP diluted EPS was $0.53 versus $1.01 a year ago, while adjusted diluted EPS, which excludes $1.362 billion of specified after-tax charges including $658 million of intangible amortization and acquisition- and legal-related costs, rose to $1.31 from $1.26.
Diagnostics and Medical Devices led performance, with comparable sales growth of 2.9% and 8.4% respectively, while Established Pharmaceuticals grew 8.7% and Nutrition declined 3.6% on a comparable basis. Abbott completed the acquisition of Exact Sciences, advancing its Cancer Diagnostics business, and highlighted progress in key pipeline programs, including completion of enrollment in the TECTONIC trial, CE Mark for the Libre Duo glucose‑ketone sensor, and FDA submission for the Amulet 360 device.
Management reaffirmed full‑year 2026 comparable sales growth guidance of 6.5%–7.5% and raised full‑year adjusted EPS guidance to $5.45–$5.60, with third‑quarter adjusted EPS projected at $1.38–$1.46. The company returned $2.1 billion to shareholders in the quarter and declared its 410th consecutive quarterly dividend of $0.63 per share.